Gene silencing shows promise for treating two fatal neurological disorders
NIH-funded preclinical studies suggest designer drug may treat ALS and spinocerebellar ataxia 2.
Source: National Institutes of Health (NIH) News Releases - Category: American Health Source Type: news
More News: American Health | Ataxia | Genetics | National Institutes of Health (NIH) | Neurology | Study